Rituximab biosimilar (Hetero Drugs)

利妥昔单抗生物类似药 (Hetero Drugs)

Report date: 2023/05/05 17:34:31

Base Information

Drug NameRituximab biosimilar (Hetero Drugs)

Drug Alias Name利妥昔单抗生物仿制药 (Hetero Drugs)MaballMabura

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[4]

Global Approved IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[4]

Approved Indications in ChinaN/A

Original Approved Country/TerritoryIndia

Original Approved Date2015/01/01

Country/TerritoryIndia

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesHetero Drugs Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHetero Drugs Ltd

Inactive CompaniesN/A

Active IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[4]

Inactive IndicationsN/A

Other Information

ATC CodeL01XC02